DBV Technologies (DBVT) Other Gross PP&E Adjustments (2018 - 2026)
DBV Technologies (DBVT) reported Other Gross PP&E Adjustments of -$8.1 million for Q1 2026, down 44.31% year-over-year from -$14.5 million in Q1 2025, and down 129.43% on a QoQ basis from $27.5 million in Q4 2025.
DBV Technologies (DBVT) has 9 years of Other Gross PP&E Adjustments data on file, last reported at -$8.1 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments fell 44.31% year-over-year to -$8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.1 million (down 44.31% YoY) and the FY2025 annual result came in at $27.5 million, up 72.14% from the prior year.
- Other Gross PP&E Adjustments retreated to -$8.1 million in Q1 2026 per DBVT's latest filing, from $27.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $27.5 million in Q4 2025 and bottomed at -$8.1 million in Q1 2026.
- The 5-year median for Other Gross PP&E Adjustments is -$3.1 million (2022), against an average of $2.2 million.
- The widest annual swing landed in 2024, when Other Gross PP&E Adjustments plunged 331.1%; it then soared 72.14% in 2025.
- Tracing DBVT's Other Gross PP&E Adjustments over 5 years: stood at $26.3 million in 2022, then declined by 1.71% to $25.8 million in 2023, then slumped by 38.08% to $16.0 million in 2024, then jumped by 72.14% to $27.5 million in 2025, then tumbled by 129.43% to -$8.1 million in 2026.
- Per Business Quant, the three latest DBVT Other Gross PP&E Adjustments figures stand at -$8.1 million (Q1 2026), $27.5 million (Q4 2025), and -$5.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | -8.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.10 Mn |
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 27.52 Mn |
| Dec 31, 2025 | 27.52 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Jun 30, 2025 | -5.78 Mn |
| Jun 30, 2025 | -5.78 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | 15.99 Mn |
| Dec 31, 2024 | 15.99 Mn |
| Sep 30, 2024 | -5.99 Mn |
| Sep 30, 2024 | -5.99 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Mar 31, 2024 | -6.55 Mn |
| Mar 31, 2024 | -6.55 Mn |
| Dec 31, 2023 | 25.82 Mn |
| Dec 31, 2023 | 25.82 Mn |
| Sep 30, 2023 | -1.39 Mn |
| Sep 30, 2023 | -1.39 Mn |
| Jun 30, 2023 | -1.83 Mn |
| Jun 30, 2023 | -1.83 Mn |
| Mar 31, 2023 | -2.13 Mn |
| Mar 31, 2023 | -2.13 Mn |
| Dec 31, 2022 | 26.27 Mn |
| Dec 31, 2022 | 26.27 Mn |
| Sep 30, 2022 | -2.61 Mn |
| Sep 30, 2022 | -2.61 Mn |
| Jun 30, 2022 | -3.15 Mn |
| Jun 30, 2022 | -3.15 Mn |
| Mar 31, 2022 | -3.36 Mn |
| Mar 31, 2022 | -3.36 Mn |
| Dec 31, 2021 | 19.09 Mn |
| Dec 31, 2021 | 19.09 Mn |
| Sep 30, 2021 | -7.88 Mn |
| Sep 30, 2021 | -7.88 Mn |
| Jun 30, 2021 | -8.63 Mn |
| Jun 30, 2021 | -8.63 Mn |
| Mar 31, 2021 | -9.17 Mn |
| Mar 31, 2021 | -9.17 Mn |
| Dec 31, 2020 | 27.31 Mn |
| Dec 31, 2020 | 27.31 Mn |
| Dec 31, 2019 | 5.23 Mn |
| Dec 31, 2019 | 5.23 Mn |
| Dec 31, 2018 | -34.70 Mn |
| Dec 31, 2018 | -34.70 Mn |